E-64C

E-64C

SCHEMBL1807396

[2H]C([2H])([2H])C(C)C[C@H](NC(=O)[C@H]1O[C@@H]1C(=O)O)C(=O)NCCC(C)C

nearest known ligand 0.86

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 15/20 0.86
CTSB P07858 3/20 0.86
CAPN9 O14815 2/20 0.86
MAPK1 P28482 2/20 0.86
CTSL P07711 3/20 0.63
LMNA P02545 2/20 0.63
CTSG P08311 1/20 0.63
CTSK P43235 2/20 0.58
CTSH P09668 1/20 0.58
CTSS P25774 1/20 0.58
CTSC P53634 1/20 0.58
CYP3A4 P08684 1/20 0.58
TSHR P16473 1/20 0.58
CYP2C19 P33261 1/20 0.58
USP2 O75604 1/20 0.58
MAPT P10636 1/20 0.58
BLM P54132 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
E-64C SCHEMBL10750447 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL3281530 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL1121089 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL14067670 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL6041204 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
E-64C SCHEMBL10933522 0.92 CAPN1 (1.00) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL20643960 0.87 CAPN1 (0.85) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL16982381 0.87 CAPN1 (0.89) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL12653370 0.83 CAPN1 (0.81) CAPN1CTSBCAPN9MAPK1CTSL
SCHEMBL12653866 0.83 CAPN1 (0.81) CAPN1CTSBCAPN9MAPK1CTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200237849-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2020-07-30 US disclosed
US-20190015472-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2019-01-17 US disclosed
US-10022418-B2 Compositions and methods for treating beta-amyloid related diseases AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) 2018-07-17 US disclosed
EP-3296295-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES American Life Science Pharmaceuticals, Inc. (US) 2018-03-21 EP disclosed
EP-2921486-B1 Compositions and methods for treating beta-amyloid related diseases AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2017-09-27 EP disclosed
US-20160058824-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2016-03-03 US disclosed
EP-2921486-A1 Compositions and methods for treating beta-amyloid related diseases American Life Science Pharmaceuticals, Inc. (US) 2015-09-23 EP disclosed
EP-2462131-B1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) 2014-10-15 EP disclosed
US-20110105603-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC. (US) 2011-05-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110105603-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES APP, BACE1, PTMS CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885
US-10022418-B2 Compositions and methods for treating beta-amyloid related diseases APP, BACE1, PTMS CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885
US-20200237849-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES APP, BACE1, PTMS CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885
US-20190015472-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES APP, BACE1, PTMS CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885
US-20160058824-A1 COMPOSITIONS AND METHODS FOR TREATING BETA-AMYLOID RELATED DISEASES APP, BACE1, PTMS CAPN1 1955/4885CTSB 381/4885CAPN9 2866/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.